abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

このページは 日本語 では利用できません。English で表示されています

記事

2006年11月14日

著者:
Reuters

World's poor still deprived of drugs - activists

Poor people in developing countries are still not getting access to many life-saving medicines five years after a trade declaration that rich countries should put patients before profits, campaigners said on Tuesday...Oxfam and AIDS groups said...rich countries, particularly the United States, were bullying developing countries to impose stricter patent rules in order to preserve pharmaceutical monopolies...[An example is]...a dispute over the cancer drug Glivec, made by...Novartis...An Indian court in January rejected its patent application for Glivec, but Novartis is fighting back, arguing that the principle of intellectual property protection must be protected if innovation is to flourish.

Part of the following timelines

Oxfam says rich countries still restrict access to medicines for the poor through patent rules that preserve pharmaceutical monopolies

Novartis lawsuit (re India patent law & access to medicine)(new)